Latest AI and machine learning research in hemophilia for healthcare professionals.
The emergence of drug resistance and off-target toxicities in epidermal growth factor receptor (EGFR) targeted therapies underscores the urgent need for novel inhibitor scaffolds. This study integrates artificial intelligence-driven generative models with experimental validation to discover novel, selective EGFR inhibitors. Utilizing REINVENT4, a reinforcement learning-based generative framework, ...
Machine learning-guided virtual screening has the potential to accelerate early-stage drug discovery, but its practical utility is often limited by uncertain generalization to different chemical scaffolds and by insufficient prospective evaluation under realistic experimental constraints. To address these challenges, we conduct a target-driven virtual screening study using TAME-VS against aldo-ket...
BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) is a common procedure for treating biliary and pancreatic disorders; however, it is ...
Emicizumab is an established prophylactic therapy for haemophilia A (HA). However, real-world multicentre evidence on long-term outcomes, particularly...
Cobalt (Co) has emerged as a promising interconnect material to replace copper. Due to its susceptibility to corrosion, controlling the balance betwee...
BACKGROUND: Dihydroorotate dehydrogenase (DHODH), an important enzyme in de-novo pyrimidine synthesis, and its dysregulation has been frequently assoc...
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that improves clinical outcomes in patients with E...
The transition from fossil fuels to low-carbon bio-based energy systems is increasingly constrained by the efficiency, scalability, and integration of...
The crystal form a drug adopts can change everything from how it dissolves to whether it works in the clinic, yet predicting which polymorphs a flexib...
BACKGROUND: Large language models (LLMs) show potential to support antimicrobial prescribing but require simulation-based, institution-specific safety...
PURPOSE: Treatment-free remission (TFR) is a major therapeutic objective in chronic myeloid leukemia (CML). However, nearly 50% of patients relapse af...
BACKGROUND: Heart failure with ischemic cause is associated with substantial cardiovascular mortality. SGLT2 (sodium glucose cotransporter 2) inhibito...
OBJECTIVE: Antimicrobial Stewardship Programs (ASPs) need healthcare economic analyses to support and inform ASP strategies. This work aimed to determ...
BACKGROUND: Preeclampsia, which is a leading cause of maternal and perinatal mortality and morbidity, represents a biologically heterogeneous syndrome...
Hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) is a heterogeneous malignancy with poor prognosis, necessitating refined classificatio...
BACKGROUND: Tissue-resident memory T (TRM) cells play a role in causing long-term tissue injury in chronic inflammatory diseases via pathological epig...
Immune checkpoint inhibitors, particularly antibodies targeting programmed cell death 1 (PD-1), are increasingly used for advanced hepatocellular carc...
BACKGROUND: SERPING1, which encodes the C1 inhibitor (C1-INH) of the complement system, and plays a key regulator in regulating inflammatory responses...
The rapid global expansion of β-lactamase-mediated antimicrobial resistance demands mechanistic approaches capable of resolving the dynamics of enzyme...
BACKGROUND: Maternal anaemia remains a pressing global health challenge, with a notable burden in low- and middle-income countries. Existing studies i...